Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $60.0833.

Several equities research analysts recently issued reports on the company. Clear Str downgraded Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Stifel Nicolaus reduced their target price on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Wolfe Research began coverage on shares of Janux Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Thursday, January 22nd.

Insider Activity at Janux Therapeutics

In related news, insider Zachariah Mciver sold 2,714 shares of Janux Therapeutics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the sale, the insider directly owned 23,286 shares in the company, valued at approximately $319,716.78. This trade represents a 10.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Alan Campbell sold 8,072 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the transaction, the chief executive officer owned 284,982 shares of the company’s stock, valued at $3,912,802.86. This trade represents a 2.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 25,699 shares of company stock valued at $471,235 in the last ninety days. Insiders own 8.10% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of large investors have recently added to or reduced their stakes in JANX. Squarepoint Ops LLC raised its position in shares of Janux Therapeutics by 230.0% in the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock valued at $4,379,000 after purchasing an additional 132,121 shares during the period. Quinn Opportunity Partners LLC grew its stake in Janux Therapeutics by 15.4% in the 2nd quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company’s stock valued at $1,384,000 after buying an additional 8,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in Janux Therapeutics by 15.5% during the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock valued at $20,845,000 after acquiring an additional 121,403 shares during the period. AlphaQuest LLC lifted its position in shares of Janux Therapeutics by 3,658.9% during the second quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock worth $224,000 after acquiring an additional 9,440 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new position in shares of Janux Therapeutics in the second quarter worth $757,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $13.71 on Friday. The stock has a market cap of $824.66 million, a price-to-earnings ratio of -8.16 and a beta of 2.88. Janux Therapeutics has a fifty-two week low of $12.80 and a fifty-two week high of $46.10. The firm’s 50-day simple moving average is $16.80 and its 200 day simple moving average is $22.34.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, sell-side analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.